S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022 - 1 of 7

 

#1 - Merck (NYSE:MRK)

Merck & Co., Inc. logo

One of the biggest stories in the pharmaceutical sector was the announcement that Merck (NYSE: MRK) was able to report stellar results on a late-stage study for its Covid-19 therapy, molnupiravir. The pill, which the company developed in partnership with Ridgeback Biotherapeutics, is likely to be a huge commercial success should it receive emergency use authorization.

This is igniting an intense debate over whether a safe and effective pill to treat Covid-19 symptoms will render vaccination efforts obsolete. For investors looking to 2022, I believe a “both/and” approach is warranted.

MRK stock gapped up nearly 10% on the announcement. But the stock is giving up some of those gains. The consensus opinion for MRK stock forecasts a 15% gain. But recent opinions that have been issued since the announcement of its Covid-19 pill suggest the stock could have even further to climb. Plus, the company reports earnings at the end of October and the stock may receive further upgrades in advance of, and immediately following the report.

About Merck & Co., Inc.

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.Read More 
Current Price
$73.34
Consensus Rating
Buy
Ratings Breakdown
8 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$95.27 (29.9% Upside)





Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.